14:06 , Mar 18, 2019 |  BC Extra  |  Financial News

Karuna looks past schizophrenia with $68M series B

Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding. By late 2019,...
19:23 , Mar 8, 2019 |  BC Week In Review  |  Financial News

Erasca extends series A by $22M

Erasca raised additional funds to enable compound in-licensing and accelerate development of its Oncology Pattern Recognition Algorithm (OPRA) for discovering cancer cures. Erasca Inc. (San Diego, Calif.) raised $22 million in a series A extension,...
17:33 , Mar 8, 2019 |  BC Week In Review  |  Financial News

Beam raises $135M series B

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May...
12:11 , Mar 6, 2019 |  BioCentury  |  Finance

Beam broadens base with $135M B round

By raising a $135 million series B round on Wednesday, base editing company Beam Therapeutics has surpassed CRISPR Therapeutics AG (NASDAQ:CRSP) for the most venture money raised by a CRISPR-based company. Added to its May...
00:47 , Mar 2, 2019 |  BC Extra  |  Company News

Emerging company roundup: Anthos, Maze, Oyster Point

In a week that had at least four companies post venture raises north of $80 million, Maze Therapeutics and Anthos Therapeutics Inc. had the biggest hauls, with financings near or above $200 million. Blackstone partnered...
19:58 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Third Rock launches Maze with $191M to target genetic modifiers

Maze Therapeutics (San Francisco, Calif.) launched Thursday with $191 million to develop treatments targeting genetic modifiers. The company is combining large-scale human genetics and functional genomics to analyze how modifier genes confer protection and how...
15:00 , Feb 28, 2019 |  BioCentury  |  Finance

Navigating Third Rock's Maze

After Third Rock Ventures incubated Maze Therapeutics for two years, the company debuted Thursday with $191 million and plans to generate data for its three genetic modifier programs in the next 3-5 years. Third Rock...
12:08 , Feb 28, 2019 |  BC Extra  |  Financial News

Third Rock launches Maze with $191M to target genetic modifiers

Maze Therapeutics (San Francisco, Calif.) launched Thursday with $191 million to develop treatments targeting genetic modifiers. The company is combining large-scale human genetics and functional genomics to analyze how modifier genes confer protection and how...
04:45 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
23:22 , Feb 13, 2019 |  BC Week In Review  |  Financial News

Arch-backed HiberCell launches with over $60M to target dormant cancer cells

HiberCell Inc. (New York, N.Y.) launched on Feb. 7 with $60.8 million in series A funding from Arch Venture Partners to develop therapies that prevent cancer relapse and metastasis. HiberCell said it is the first...